Novozymes A/S Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Novozymes A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View analyst ratings for Novozymes A/S or view top-rated stocks.

Wall Street analysts have given Novozymes A/S a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novozymes A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Novozymes A/S saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 3,900 shares, an increase of 44.4% from the June 30th total of 2,700 shares. Based on an average trading volume of 11,400 shares, the short-interest ratio is presently 0.3 days.
View Novozymes A/S's Short Interest.

Novozymes A/S is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Novozymes A/S.

Novozymes A/S (OTCMKTS:NVZMY) posted its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.42 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.42. The biotechnology company had revenue of $558.75 million for the quarter. Novozymes A/S had a net margin of 20.72% and a trailing twelve-month return on equity of 26.92%.
View Novozymes A/S's earnings history.

Novozymes A/S's stock was trading at $45.0314 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVZMY shares have increased by 68.3% and is now trading at $75.77.
View which stocks have been most impacted by COVID-19.

Novozymes A/S announced a dividend on Monday, March 1st. Shareholders of record on Monday, March 15th will be paid a dividend of $0.8492 per share on Wednesday, March 31st. This represents a dividend yield of 1.38%. The ex-dividend date is Friday, March 12th.
View Novozymes A/S's dividend history.

Novozymes A/S pays an annual dividend of $0.56 per share and currently has a dividend yield of 0.74%. The dividend payout ratio of Novozymes A/S is 36.60%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 30.77% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.
View Novozymes A/S's dividend history.

Some companies that are related to Novozymes A/S include BioNTech (BNTX), Biogen (BIIB), PharmaCyte Biotech (PMCB), Seagen (SGEN), Bio-Techne (TECH), argenx (ARGX), Novavax (NVAX), Repligen (RGEN), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI) and Halozyme Therapeutics (HALO).
View all of NVZMY's competitors.

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVZMY stock can currently be purchased for approximately $75.77.

Novozymes A/S has a market capitalization of $17.29 billion and generates $2.15 billion in revenue each year. The biotechnology company earns $432.79 million in net income (profit) each year or $1.53 on an earnings per share basis.

Novozymes A/S employs 6,185 workers across the globe.

The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.

Novozymes A/S was founded in 2000.

The official website for Novozymes A/S is www.novozymes.com.

Novozymes A/S is headquartered at Krogshoejvej 36, Bagsvaerd G7, 2880.

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]